Announcements – Neville Registrars

16 JANUARY 2020

Elecosoft PLC : Launch of new AI visualisation tool

RNS Number : 9495Z Elecosoft PLC 16 January 2020 Elecosoft Plc ("Elecosoft" or the "Company") Launch of its new Artificial Intelligence visualisation tool Elecosoft (AIM: ELCO), announces the launch of its new Artificial Intelligence ("AI") software tools at the Domotex Show in Hanover in January 2020. The new AI……

08 JANUARY 2020

Midatech Pharma PLC : Positive Results from MTD201-102 Study

RNS Number : 0622Z Midatech Pharma PLC 08 January 2020 8 January 2020 Midatech Pharma PLC ("Midatech" or the "Company") Positive Results from MTD201-102 Study Support Subcutaneous Route for Long-Acting Octreotide Product Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering……

RNS Number : 0622Z

Midatech Pharma PLC

08 January 2020

8 January 2020

Midatech Pharma PLC

("Midatech" or the "Company")

Positive Results from MTD201-102 Study Support Subcutaneous Route for Long-Acting Octreotide Product

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce positive headline results from Study 102. The study met its primary endpoints to confirm similar pharmacokinetics and bioavailability of octreotide for subcutaneous and intramuscular routes of administration.

The results demonstrate that MTD201 can deliver sustained plasma octreotide concentrations within the range needed for therapeutic efficacy with an injection interval of six to eight weeks by either subcutaneous or intramuscular administration.

These are key advantages for patients, payors and physicians over the current standard of care. The subcutaneous route of administration is simpler, less painful, and allows the potential for self-administration at home, with less need for hospital visits or nurse supervision to receive treatment. An extended dose interval would reduce the annual treatment burden for patients from 12 to just 6 injections per year, thus providing a much less frequent, more cost effective and patient friendly treatment regimen. These attributes are in addition to already demonstrated advantages for MTD201, including less painful injections due to smaller needle size (21 gauge needle, compared to 19/18 gauge for SLAR), simpler, more reliable reconstitution and injection (less than 10 minutes versus up to 40 minutes for SLAR), and flexibility for unit doses above 30mg.

Study 102 investigated the subcutaneous administration of MTD201 as an additional alternative injection route to intramuscular administration, and determined the preferred administration route to take forward into the MTD201 registration study to be commenced in mid 2020. The primary endpoints were to determine the relative plasma octreotide bioavailability and pharmacokinetics of MTD201 deep subcutaneous injection, MTD201 deep intramuscular injection and Sandostatin® Octreotide Acetate Injection deep subcutaneous injection. The study was conducted in 28 healthy subjects and following a single injection of MTD201 (either subcutaneously or intramuscularly) in early October 2019, all subjects entered a 63-day observation and sampling period to determine plasma octreotide and insulin-like growth factor-1 (IGF-1) concentrations.

The key preliminary results from Study 102 include:

· Pharmacokinetics ("PK")

o both subcutaneous and intramuscular injections produced a similar overall extended octreotide PK profile

o the octreotide release profile supports injection intervals of up to eight weeks, compared to the predominantly 4 weekly current standard of care

o inter-subject variability for MTD201 was consistent with that observed for currently commercialised long-acting octreotide products

· Pharmacodynamics ("PD")

o sustained reduction in plasma IGF-1 throughout the 63-day assessment period was similar for both subcutaneous and intramuscular injections

· Safety

o MTD201 was very well tolerated. Results show that adverse events were similar for both subcutaneous and intramuscular injections. There were only minor and transient injection site reactions with no differences between the injection routes

Preparation for commencement of the next pivotal study for the clinical development for MTD201 is now underway, which is planned to commence later in H1 2020. A pivotal registration programme to support a second indication in NET is also expected to commence in 2020.

Commenting Craig Cook, CEO of Midatech, said: "We are very pleased with the positive results of Study 102. It confirmed both the subcutaneous dosing route for MTD201, as well as the potential for extended dosing intervals. These are key advantages for patients, physicians and payors, being the first therapy to offer this, and also gives Midatech a competitive advantage versus others as we move the product through to potential approval."

For more information, please contact:

Midatech Pharma PLC

Dr Craig Cook, CEO

Stephen Stamp, CFO

Tel: +44 (0)1235 888300

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: [email protected]

Edison Group (US Investor Relations)

Joseph Green/ Laine Yonker

(646) 653-7030/ 7035

[email protected]/ [email protected]

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

· Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

· MidaSolve™ platform: an innovative nano-technology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

· MidaCore™ platform: a leading edge nano-technology used for targeting medications to sites of disease.

By improving biodelivery and biodistribution of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks, accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's headquarters and R&D facility is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the potential treatment options for MTD201 and the development of the programme.

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RESEAPFXESKEEFA

Close

03 JANUARY 2020

Neville Registrars welcomes NetScientific plc

Neville Registrars is delighted to welcome NetScientific plc as the newest addition to its list of client companies. NetScientific is a transatlantic healthcare IP commercialisation group which funds and develops companies that significantly improve the health and well-being of people with chronic diseases. Further information can be found on the Company's website: https://netscientific.net/…

23 DECEMBER 2019

Crimson Tide PLC : Significant long-term contract and trading update

RNS Number : 7385X Crimson Tide PLC 23 December 2019 Crimson Tide plc ("Crimson Tide" or the "Company") Significant long-term contract win and trading update Crimson Tide (TIDE) announces that it has entered into a significant long-term contract for its mpro5 solution with one of the……

20 DECEMBER 2019

Immotion Group PLC : Trading update – continued roll-out of headsets

RNS Number : 5690X Immotion Group PLC 20 December 2019 Immotion Group plc ("Immotion Group", the "Company") Trading update – continued roll-out of headsets Immotion Group, the UK-based immersive virtual reality ("VR") 'Out of Home' entertainment group, is pleased to provide a trading update. In particular, the……

RNS Number : 5690X

Immotion Group PLC

20 December 2019

Immotion Group plc

("Immotion Group", the "Company")

Trading update – continued roll-out of headsets

Immotion Group, the UK-based immersive virtual reality ("VR") 'Out of Home' entertainment group, is pleased to provide a trading update. In particular, the Company has grown its installed headset base to 302. The split of headsets is currently as follows:

Segment	Headsets

Immotion VR	117
Partners	185

Total	302

Based on our visible pipeline, we expect to see a significant acceleration in new installation activity as we go into the New Year. We believe that our existing estate, combined with expected headset installations, will result in an installed base that should deliver monthly underlying EBITDA breakeven (based on our forecasted operating costs) by or around the end of Q1 2020.

As previously announced on 30 July 2019, we are now focusing on our Partner model and more particularly, in the short term, on the aquarium sector. We have found that higher yielding opportunities are offered by "edutainment" verticals, and have shied away from the more general family entertainment centre market, which we believe is too crowded.

We have seen significant interest from large numbers of aquaria, in both the USA and Europe, and we expect the majority of our installations in the short term to be in this segment. As we anticipated, this segment has outperformed the overall Partner segment, with average weekly revenue per headset, in the year to date, of £442, compared to an overall Partner average of £305. We expect the average Partner revenue per headset to grow strongly as we increase the number of aquaria installations in the overall blend.

Whilst the initial appeal of our offering for partners has been ancillary revenue from a small footprint (2-4 headsets), we are beginning to see demand from very high traffic destinations for larger installations. These could become key exhibits in their own right and become more integral to the visitor experience. We will update the market as these opportunities develop.

Consequently, we are very pleased to announce that following a successful trial at Sea Life London Aquarium, we will be increasing our installed headset base there from four to eight headsets to accommodate demand, creating a mini-themed cinema.

We will also look to build on the early success of our location tailored Tower Coaster offering. We have been able to design a 400-foot VR roller coaster ride over individual cityscapes, giving us the ability to provide a unique product to high footfall locations. This product has already been successfully deployed in Blackpool, at the iconic Blackpool Tower, operated by Merlin Entertainments. We are currently in discussions with a number of other landmark destinations about this product.

Our nine own operated and staffed locations, trading as Immotion VR, have operated profitably, and whilst we do not intend to open further locations, preferring the Partner model, we will continue to seek to optimise the performance of these operations.

We expect 2019 full year underlying EBITDA loss to be in line with expectations and revenue to be in the range of £3.6-£3.8m, (towards the lower end of expectations).

On a pro forma basis, the current average Partner weekly revenue per headset (£305) across the 185 installed partner headsets would generate annualised revenue of circa £3m. For 2020 we will focus on the higher yielding installations such as aquaria (£442 average weekly revenue per headset, year to date) and other "edutainment" verticals which we believe could offer similar returns.

To this end in Q1 2020, we expect to launch exciting new "edutainment" experiences aimed at family-focused, high traffic destinations such as zoos; science centres and museums.

Martin Higginson, Immotion Group CEO, said:

"We are pleased with the increasing momentum of interest in and uptake of our Partner offerings. We remain of the view that this is the right path in order to scale our business rapidly and to build a market leading position in the 'out of home' VR market.

We have seen really strong traction in the Aquarium sector and it is clear we have a compelling offer that is delivering strong results for ourselves and our partners. Take-up in this sector continues to be growing and we are also beginning to see interest in larger more 'integrated' installations.

Our Tower Coaster experience is proving extremely popular and we now have this operating in three UK cities with more enquiries coming through. The ability to be able to offer a tailored roller coaster experience 400 feet above a particular cityscape is a unique offering with global potential.

We also have some really exciting new experiences in development, which will allow us to open up other large global markets, such as zoos, science centres and museums.

Q1 2020 should be extremely busy and exciting for the Group. We move towards 2020 with growing confidence in our strategy, which is designed to allow us to scale rapidly. We look forward to updating the market further."

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

Enquiries:

For further information please visit www.immotion.co.uk, or contact:

Immotion Group	Martin Higginson	Tel: +44 (0) 161 235 8505
WH Ireland Limited (Nomad and Joint Broker)	Adrian Hadden Darshan Patel Matthew Chan	Tel + 44 (0) 207 220 1666
Shard Capital Partners LLP (Joint Broker)	Damon Heath Erik Woolgar	Tel: +44 (0) 20 7186 9900
Alvarium Capital Partners	Alex Davies	Tel: +44 (0) 207 195 1433

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

TSTDBBDDDBBBGCC

Close

16 DECEMBER 2019

ValiRx PLC : VAL201 Update

RNS Number : 9024W ValiRx PLC 16 December 2019 VALIRX PLC ("ValiRx", the "Company" or the "Group") VAL201 UPDATE "Positive Phase I/II data compiled" London, UK., 16 December 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides an update on……

RNS Number : 9024W

ValiRx PLC

16 December 2019

VALIRX PLC

("ValiRx", the "Company" or the "Group")

VAL201 UPDATE

"Positive Phase I/II data compiled"

London, UK., 16 December 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides an update on the clinical progress of VAL201, ValiRx's lead Phase I/II therapeutic compound, for the treatment of prostate cancer and other indications of hormone-induced unregulated growth, including endometriosis.

As the Company anticipated in March 2019, the VAL201 trial is coming to a conclusion. The trial data collected to date is undergoing collation and verification, in addition to statistical and scientific analysis. This is prior to its submission to the relevant regulatory authorities. Until regulatory approval has been reached and all the trial data has been verified, limited preliminary observations can be inferred.

The results appear, in advance of full analysis, to indicate that the VAL201 compound has a clear impact on patients with prostate cancer, as measured by PSA – evidence that is supported from tumour imaging (MRI and CT) in subjects. The compound has also shown it is very safe and has a high degree of tolerability, up to a dose that is in excess of the predicted dose and any practical therapeutic concentration.

The results, along with a full statistical and scientific analysis, will be submitted to the relevant regulatory authorities as is required, at which point the detailed results will be made publicly available. However, in the interim, it is intended that the trial's preliminary observations may be presented at various academic conferences, as part of the compound's ongoing reporting and analysis.

Scientific Summary:

· All data collected to date during the clinical trial of VAL201, is currently being reviewed and collated by the data analytics team.

· The data will be secured after it has been entered into the record, collated and verified, whilst some additional data is still to be collected from various providers, contractors and from patients and then entered into the record.

· Beyond the fundamental safety and tolerability endpoints for the trial, the study is providing accurate pharmacokinetic information about the uptake, distribution, metabolism and elimination of the compound in humans. As such, VAL201 continues to address its endpoints in its first-in-human study.

· A late-stage study designed to determine the overall effectiveness of VAL201 and the most effective therapeutic strategies for its use in disease management, is now possible. This late-stage study will be designed and set up, in parallel to the conclusion of the current early-stage Phase I/IIa trial.

VAL201 has been developed in collaboration with Cancer Research (CRUK) and is a decapeptide with potential in treating hormone-dependent and hormone-independent prostate cancer, currently a poorly served multi-billion dollar commercial market.

Dr Satu Vanikka, CEO of ValiRx Plc, commented:

"With prostate cancer reported this month in an academic study as being the most common cancer in men in the UK* and with an estimated 1.3 million new cases of prostate cancer occurring worldwide last year**, it is truly exciting to see VAL201 approaching the conclusion of its Phase I/II first-in-man study."

"I look forward to regulatory approval of the trial data being speedily reached and the opportunity of potentially demonstrating that VAL201 can address this widespread and often fatal disease in men."

Sources:

*https://www.bristol.ac.uk/news/2019/december/prostate-cancer.html

** Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries by Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A in CA: A Cancer Journal for Clinicians

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

*** ENDS ***

For more information, please contact:

ValiRx plc	Tel: +44 (0) 20 3008 4416 www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.	Tel: +44 (0) 7879 458 364 [email protected]

Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880

Allenby Capital Limited (Joint Broker) Jeremy Porter / Alex Brearley (Corporate Finance) Kelly Gardiner (Equity Sales)	Tel: +44 (0) 20 3328 5656

Novum Securities Limited (Joint Broker) Colin Rowbury	Tel: +44 (0) 20 7399 9400

Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

MSCFFWFWLFUSEEE

Close

06 DECEMBER 2019

Chamberlin PLC : Contract award for Walsall foundry

RNS Number : 8844V Chamberlin PLC 06 December 2019 AIM: CMH 6 December 2019 CHAMBERLIN PLC ("Chamberlin" or the "Company") Contract award for Walsall foundry Chamberlin, the specialist casting and engineering group, is pleased to announce the successful award of new business to supply……

06 DECEMBER 2019

Chamberlin PLC : Contract award for Scunthorpe foundry

RNS Number : 8839V Chamberlin PLC 06 December 2019 AIM: CMH 6 December 2019 CHAMBERLIN PLC ("Chamberlin" or the "Company") Contract award for Scunthorpe foundry Chamberlin, the specialist castings and engineering group, is pleased to announce the award of a significant new order for……

02 DECEMBER 2019

Neville Registrars welcomes OneView Group Limited

Neville Registrars is delighted to welcome OneView Group Limited as the newest addition to its list of client companies. …

25 NOVEMBER 2019

Modern Water PLC : Sale of AMBC for Korea Salt Production Facility

RNS Number : 5212U Modern Water PLC 25 November 2019 Modern Water plc ("Modern Water", "the Company" or "the Group") Modern Water sells its largest-ever AMBC for Korea Salt Production Facility For immediate release 25 November 2019 Modern……

Chamberlin plc Kevin Nolan, Chief Executive Neil Davies, Finance Director		T: 01922 707100

Cenkos Securities plc (Nominated Adviser and Broker) Russell Cook Katy Birkin		T: 020 7397 8900

KTZ Communications (Financial PR) Katie Tzouliadis Dan Mahoney		T: 020 3178 6378

Chamberlin plc Kevin Nolan, Chief Executive Neil Davies, Finance Director		T: 01922 707100

Cenkos Securities plc (Nominated Adviser and Broker) Russell Cook Katy Birkin		T: 020 7397 8900

KTZ Communications (Financial PR) Katie Tzouliadis Dan Mahoney		T: 020 3178 6378